Pine Valley Investments Ltd Liability Co Cuts Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Pine Valley Investments Ltd Liability Co lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 9.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,141 shares of the medical device company’s stock after selling 538 shares during the quarter. Pine Valley Investments Ltd Liability Co’s holdings in DexCom were worth $400,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc acquired a new position in DexCom in the 4th quarter valued at $25,000. Heck Capital Advisors LLC purchased a new stake in shares of DexCom during the fourth quarter worth $38,000. Midwest Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $54,000. RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom in the third quarter worth about $57,000. Finally, Rothschild Investment LLC lifted its stake in shares of DexCom by 250.5% in the fourth quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock worth $58,000 after buying an additional 536 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research reports. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group upped their price target on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Wells Fargo & Company upped their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.06.

DexCom Stock Performance

Shares of DXCM stock opened at $89.91 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market cap of $35.13 billion, a P/E ratio of 62.87, a P/E/G ratio of 2.30 and a beta of 1.14. The firm’s 50 day moving average price is $84.29 and its 200-day moving average price is $76.47. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,083 shares of company stock valued at $3,309,794. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.